MDWD logo

MEDIWOUND LTD

MDWDNASDAQ
🏆 #3674 by market capUS Equity
——
Quote unavailable
🔔
Track MDWD
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$175M
Small Cap
📈Revenue Growth (YoY)
-16.1%
Declining
📊Gross Margin
15.5%
Thin
💵FCF Margin
-239.3%
Thin
⚖️P/S Ratio
14.8x
Expensive
Otter Score
—
Insufficient data
No chart data available for MDWD.

Trading Snapshot

Day Range
—
52-Week Range
$11.80 – $19.70
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
12.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$17M
Last Q Revenue
$3M
P/E Ratio
-8.5
P/S Ratio
14.8x
EPS (TTM)
$-1.57
Dividend Yield
0.00%
Dilution (1yr)
+18.9%
MDWD logo

MEDIWOUND LTD

MDWD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17M▼ −16.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
19.2%▲ +47.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$25M▲ +30.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▲ +0.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.8M▲ +18.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$3M▼ −$6M YoY
StockOtter · stockotter.space

About MEDIWOUND LTD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.